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Comparison of Gemfibrozil Versus 
Simvastatin in Familial Combined 
Hyperlipidemia and Effects on
Apolipoprotein-B-Containing Lipoproteins
Low-Density Lipoprotein Subfraction
Profile, and Low-Density 
Lipoprotein Oxidizability
Sebastian J.H. Bredie, MD, Tjerk W.A. de Bruin, MD, Pierre N.M. Demacker, PhD, 
John J.P. Kastelein, MD, and Anton F.H. Stalenhoef, MD
We evaluated in a double-blind, placebo-controlled,
randomized trial of 45 well-defined patients with famil­
ial combined hyperlipidemia, the effect of gemfibrozil 
(1,200 mg/day) or simvastatin (20 mg/day) on apo- 
lipoprotein-B (apo-B)-containing lipoproteins, low-den- 
sify lipoprotein (LDL) subfraction profile, and LDL oxidiz­
ability. Although both drugs reduced plasma cholesterol 
and triglyceride concentrations, gemfibrozil reduced 
plasma triglycerides more effectively and simvastatin 
reduced plasma cholesterol more effectively. LDL cho­
lesterol was reduced with simvastatin. With Doth drugs, 
total serum apo-B concentration decreased. With gem­
fibrozil, this was due to an exclusive reduction (-46%) 
of very low/intermediafe-density lipoprotein (VLDL + 
IDL) apo-B, whereas simvastatin decreased apo-B in 
both VLDL + IDL and LDL (34% and 15%, respectively). 
Initially, a dense LDL subfraction profile was present in
all patients. The decrease in LDL cholesterol with sim­
vastatin was due to a decrease in all isolated LDL sub- 
fractions except LDL2; gemfibrozil increased LDL1 and 
LDL2 cholesterol (p = 0.001) and reduced LDL4 choles­
terol, resulting in a more buoyant LDL subfraction pro­
file compared with simvastatin. In both groups, a pre­
dominance of small dense LDL remained despite 
therapy. LDL fatty acid composition showed a shift from 
oleic acid to linoleic acid after gemfibrozil; arachidonic 
acid increased after simvastatin. Vitamin E was lower 
after gemfibrozil. In the measurements of LDL oxidation, 
only the oxidation rate was significantly reduced with 
simvastatin. Thus, quantitative and aualitative changes 
of LDL cholesterol had only a small effect on total in 
vitro LDL oxidizability in this population with familial 
combined hyperlipidemia.
(Am J Cardiol 1995;75:348-353)
Familial combined hyperlipidemia is.a metabolically and genetically heterogeneous lipid disorder,1"3 with 
affected persons exhibiting elevations o f total choles­
terol, triglycerides, or both, at least partially caused by 
very-low-density lipoprotein (VLDL)-apolipoprotein-B 
(apo-B) overproduction.4 Its prevalence is estimated to 
be 0.5% to 1.0%,2 and the trait predisposes to premature 
cardiovascular complications.1,5 Because of the absence 
of a specific metabolic parameter characteristic of famil­
ial combined hyperlipidemia, family studies are pivotal 
for diagnosis. The current diagnosis is based on the fol­
lowing criteria1,6: prevalence of multiple lipoprotein 
phenotypes in first-degree relatives, premature athero­
sclerosis, decreased high-dcnsity lipoprotein (HDL) cho-
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lesterol levels, elevated plasma levels of apo-B,7 im­
paired clearance of VLDL remnants,8 and an increased 
prevalence of small dense low-density lipoprotein (LDL).7 
A predominance of small LDL and its enhanced sus­
ceptibility to copper-mediated oxidative modification9 is 
associated with atherogenesis.10,11 Because of the report­
ed increased risk for premature atherosclerosis, treatment 
with lipid-lowering drugs is frequently indicated.12,13 In 
this report we described the baseline lipoprotein con­
centrations, LDL subtraction profiles, and LDL oxidiz­
ability of well-defined patients with familial combined 
hyperlipidemia, and compared the effectiveness of treat­
ment with gemfibrozil or simvastatin on these parame­
ters in a double-blind, placebo-controlled fashion.
METHODS
Subjects: In all, 81 outpatients with familial combined 
hyperlipidemia were selected by 3 participating centers 
to evaluate the effect of treatment with either gemfibrozil 
or simvastatin on serum lipids. Forty-five patients from 
the 3 centers were randomly assigned for more exten­
sive biochemical studies. They participated after in­
formed consent was obtained. At entry into the placebo 
baseline period, patients met the following inclusion cri­
teria: total serum cholesterol >6.5 mmol/L and triglyc­
eride level between 2.3 and 5.6 mmol/L; at least 1 first-
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degree relative with significant hypercholesterolemia, 
hypertriglyceridemia, or both; a positive family history 
of premature coronary artery disease; total apo-B 100 
levels >1,200 mg/dl; and age >30 years. Patients with 
secondary causes for dyslipidemia or with apolipopro- 
tein phenotype E 2/2 were excluded.
Study design: This study was a double-blind, place­
bo-controlled trial with a double-dummy design, divid­
ed into 3 consecutive periods over 20 weeks, During the 
first period (weeks -8  to -5 ), selected patients who had 
taken no lipid-lowering drugs for >4 weeks received a 
standard lipid-lowering diet. The second period (weeks 
-4  to day 0) was a baseline placebo period. Each patient 
received 2 bottles, 1 containing placebo matching gem­
fibrozil and 1 containing placebo matching simvastatin. 
During the third period of active treatment (day 0 to 
week 12), patients were randomly assigned to receive 
either simvastatin 20 mg/day together with placebo 
matching gemfibrozil (n = 23) or gemfibrozil 1,200 
mg/day together with placebo matching simvastatin (n 
= 22). In the present study, data obtained at the end of 
the placebo period (day 0) were compared with results 
obtained at the end of the period of active treatment (day
84).
Plasma: Blood samples were obtained after an over­
night fast and collected in vacutainers containing 1 
mg/ml of ethylenediaminetetraacetic acid. Plasma was 
isolated immediately and a saccharose solution (600 
mg/ml H20 )  was added to prevent denaturation of LDL 
during freezing; samples were stored at -80°C for 4 to 
15 weeks. All measurements were obtained in the lipid 
research laboratory of the University Hospital Nijmegen.
Analytic methods: VLDL + intermediate-density lipo­
protein (IDL) (density [d] <1.019 g/ml) were isolated by 
ultracentrifugation for 16 hours at 40,000 rpm in a fixed 
angle rotor (TFT 45.6 rotor, Kontron, Zürich) in a Beck­
man L7-55 ultracentrifuge (Beckman, Palo Alto, Cali­
fornia).14 After removal of VLDL + IDL, cholesterol and 
triglycerides were measured in the remaining plasma and 
in total plasma. HDL was isolated from whole plasma 
by the polyethylene glycol method.15 All cholesterol and 
triglyceride measurements were determined by enzy­
matic methods (Boehringer-Mannheim, Mannheim, 
Germany [catalog no. 237574], and Sera Pak, Miles, 
Tournai, Belgium [catalog no. 6669], respectively) with 
a centrifugal analyzer (Multistat: III, Instrumentation 
Laboratory, Lexington, Massachusetts). VLDL + IDL 
cholesterol and triglycerides were calculated by sub- 
traction. Apo-B concentrations in total plasma and in 
fractions that remained after VLDL + IDL removal were 
determined by nephelometry.16 To improve the accura­
cy o f  the results, the values obtained in our laboratory 
were recalculated on the basis of values determined by 
radioimmunoassay, standardized by the International 
Union of Immunological Societies, in 40 specially 
selected fresh frozen control sera provided by Dr. S. 
Marcovina (Northwest Lipid Research Laboratory, Seat­
tle» Washington). VLDL + IDL apo-B was calculated by 
subtraction.
Low-density lipoprotein subfractionation: LDL sub­
fraction analysis before and after treatment was per­
formed by density gradient ultracentrifugation.14 For
each patient at both occasions, this analysis was per­
formed in the same run. After ultracentrifugation, the 
LDL subfractions were visible as distinct bands in the 
middle of the tube. Up to 5 LDL subtractions could be 
distinguished concentrated in the following density 
ranges: LDL1 (1.030 to 1.033 g/ml), LDL2 (1,033 to 
1.040 g/ml), LDL3 (1.040 to L045 g/ml), LDL4 (1.045 
to 1.049 g/ml), and LDL5 (1.049 to 1.054 g/ml). The 
ultracentrifugation tubes, containing LDL subfractions 
stained with Coomassie Briljant Blue R, were placed in 
a specially designed rack and photographed. Accurate 
documentation of the different LDL subfraction patterns 
was obtained by scanning the slides in triplicate on an 
LKB 2202 ultrascan laser densitometer (Pharmacia 
LKB, Uppsala, Sweden). The mean relative peak heights 
(h I to h5) o f  the LDL subfractions (LDL1 to LDL5) on 
the 3 scans were used to calculate parameter K as a con­
tinuous variable, to describe each individual LDL sub- 
fraction pattern.17 When LDL4 or LDL5, or both, were 
delected, their relative peak heights were included in the
formula LDL[100%] = LDLl[% hl] + LDL2[%h2] + 
LDL3[%h3] by converting %h3 into %h3/ in which 
%h3' = (%h3 + %h4 + %h5), Variable K was calculat­
ed by: K = (%hl -  %h3')/(%h2 -  %h 1 + !) .J7 A nega­
tive value (-1  <K <0) reflects a dense subfraction pro­
file, an intermediate subtraction profile is described by 
K = 0, and a complete buoyant profile delivers a posi­
tive K value (0 <K < l) . After photography, the LDL sub- 
fractions were accurately isolated by aspiration with a 
rubber bulb pipet, and total cholesterol content o f each 
subfraction was determined,
Determination of fatty acids and vitamin E in low-den- 
sity lipoprotein: Analysis of fatty acids, extracted from 
LDL by vortex mixing with 3 ml n-hexane, was per­
formed by gas chromatography (Varian 3400 GC, 
Houten, The Netherlands).18 Vitamin E concentrations 
were determined by high-performance liquid chro­
matography (HPLC Spectra Physics model 8800, Bre­
da, The Netherlands), with fluorescence detection.14 For 
extraction o f vitamin E, 0.2 ml LDL was vortex-mixed 
with 2 ml acetone and 2 ml petroleum ether.
Oxidation of low-density lipoproteins: The oxidation 
experiments were performed as described by Esterbauer 
et ill,19 with modifications by Kleinvekl et al.2(>
Statistics: Results are expressed as mean ± SD. Sta­
tistical analysis of alterations wilhin I group of treat­
ment was performed with W ilcoxon’s signed rank test. 
Differences in percentages between the 2 groups o f treat­
ment were analyzed with W ilcoxon’s rank sum test. A 
2-tailed probability value <0.05 was considered signifi­
cant. Statistical analyses were performed with proce­
dures available in the SPSS PC+ (Statistical Package for 
the Social Sciences) software package version 4.0,
RESULTS
P
Patients: At entry into the placebo period, all 45 
A atients described in this study met the inclusion crite­
ria. Therefore, all patients had hyperlipidemia phenotype 
IIB. The groups consisted of 5 women and 17 men in 
the gemfibrozil group and 18 men and 5 women in the 
simvastatin group (mean age 53.9 ±  9.8 vs 53.1 ± 10.3 
years, respectively; body mass index 27*4 ± 3.1 vs 26.6
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± 2.9 kg/m2, respectively). Both age and body mass 
index were similar in both groups. The iipid and lipopro­
tein levels, body mass index, and age of the 45 patients 
were equal compared with the initial population.
Effect of treatment on plasma lipid and lipoprotein lev­
els: The lipid and lipoprotein levels of the patients with 
familial combined hyperlipidemia before and after treat­
ment with gemfibrozil (n = 22) or simvastatin (n = 23) 
are summarized in Table I. There were no significant dif­
ferences in lipid concentrations between the 2 groups at
TABLE I Changes in Lipids and Lipoprofeins in Subjects With Familial Combined 
Hyperlipidemia After Treatment With Gemfibrozil or Simvastatin
Before After Change (%) p Value
Total cholesterol
G 7.54 ± 1 .1 3 6.51 ± 0.91 -12,9  ±1 1 .7 <0.001
S 7.15 ± 0.87 5.58 ± 1.12 -22.2  ± 9.4* <0.001
Triglycerides 4
G 2.90 ± 0.91 1.42 ± 0.41 -48.1 ± 18.0 <0,001
S 3.27 ± 1.19 2,61 ± 0,86 -15.9  ± 25.8Î 0.003
VLDL + IDL
triglycerides
G 2.24 ± 0.77 0.96 ± 0,38 -54.5  ± 20.0 <0,001
S 2.58 ± 1.02 2.04 ± 0.74 -15.1 ± 24.2Î 0,005
VLDL + IDL
cholesterol
G 2.2Ó ± 0 7 6 0.99 ± 0,47 -55.3 ± 30.3 <0,001
S 2.65 ± 0,90 1,50 ± 0.51 -40.9  ± 18,1* <0.001
LDL cholesterol
G 4.36 ± 0.86 4.59 ± 0.92 +9,3 ± 3ó.ó NS
S 3.Ó8 *  1.01 3.12 ± 0.98 -13.3 ± 21,6* <0.001
HDL cholesterol
G 0.92 ± 0 .1 8 1.06 ± 0.26 4-15.3 ± 20.9 0.003
S 0.82 ± 0.21 0.94 ± 0,21 + 16,8 ± 13.1 <0.001
Apo-B
G 2,136 ± 410 1,644 ± 388 -21.1 ± 20.7 <0,001
S 2,029 ± 4 1 3 1,522 ± 406 -25.2  ± 9,9 <0.001
*p  <0,01, ip  <0.001; gemfibrozil versus simvastatin.
Values are presented in mmol/L a s  mean ± SD.
Apo-B *  apolipoproteirvB; G *  gemfibrozil (n -  22); HDL ■ high*donsity lipoprotein; IDL « 
¡ntermodiafe-donsily lipoproletn; S *» sfmvaslailn (n « 23); VLDL « very-low-densily lipoprotein.
I  p l > P l
APO-B RELATED CHOLESTEROL (mmo
FIGURE 1. Correlation between total apolipoproteirvB (apo-B)-related cholesterol 
(total plasma cholesterol minus high-density lipoprotein cholesterol) (in mmol/L) 
and total plasma apo-B (closed sauares), very-low-density lipoprotein + interme- 
diate-denstty lipoprotein apo-B (plus signs), and low-density lipoprotein apo-B 
(open squares) (in mg/L) in 45 patients with familial combined hyperlipidemia.
baseline. Gemfibrozil significantly affected total triglyc­
eride levels in plasma as well as in the VLDL + IDL 
fraction, whereas simvastatin induced the largest reduc­
tion in total plasma cholesterol. On the other hand, 
VLDL + IDL cholesterol was reduced with both thera­
pies to the same extent. The largest contribution to the 
reduction in total cholesterol and triglycerides was gen­
erated by a decrease in the VLDL + IDL fraction. LDL 
cholesterol only decreased with simvastatin, and even 
tended to increase after gemfibrozil HDL cholesterol
levels increased with both drugs.
Effect of treatment on apolipoprotein-B 
lipoproteins: A  significant correlation was 
found between apo-B and total apo- 
B-related cholesterol (total cholesterol 
minus HDL cholesterol) (Pearsons’ cor­
relation coefficient 0.91; p = 0.001) (Fig­
ure 1). The concentrations of VLDL + 
IDL cholesterol and LDL cholesterol also 
correlated with their related apo-B con­
tent (correlation coefficient 0.70; p = 
0.001; 0,63; p = 0.001, respectively). Both 
therapies reduced total apo-B to a similar 
extent. Gemfibrozil reduced apo-B only in 
the VLDL + IDL fraction, whereas sim­
vastatin reduced apo-B in the VLDL + 
IDL and in the LDL fraction (Figure 2).
Effect of therapy on low-density lipopro­
tein subfraction profile and K value: Ini­
tially in all patients, LDL consisting of a 
limited number of LDL subfractions, with 
a predominance of intermediate dense 
(LDL2) and small dense (LDL3 and 
LDL4) subfractions. In 3 of 45 LDL sub­
fraction profiles, a clear, very dense LDL5 
band could be distinguished, which in all 
cases completely disappeared after treat­
ment (1 after gemfibrozil and 2 after sim­
vastatin). This sporadic LDL5 appear­
ance, in 3 patients with lipoprotein levels 
comparable to the other subjects, was 
excluded from further statistical analysis, 
Gemfibrozil treatment induced a less 
dense LDL subfraction profile, without a 
reduction in total LDL cholesterol, con­
sisting of LDLl to LDL4, with a pre­
dominance of LDL 1 to LDL3 as the main 
LDL subfractions (Figure 3), The ratio of 
cholesterol/triglyceride within the LDL 
particle increased, whereas that of Iriglyc- 
eride/apo-B decreased, probably due to a 
reduction in triglycerides per LDL parti­
cle. The ratio of cholesterol/apo-B did not 
change (Table II). Simvastatin treatment 
reduced total LDL, but did not induce a 
major shift to a less dense LDL subfrac­
tion profile as seen with gemfibrozil. The 
amount of cholesterol in all LDL sub­
fractions, except LDL2, was significantly 
reduced (Figure 3). Neither the ratio of 
cholesterol/triglyceride nor the ratio of 
cholesleroI/apo-B or triglyceride/apo-B
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changed significantly (Table II). The val­
ue o f parameter K increased more after 
gemfibrozil (-0.55 ± 0.18 to -0 .32 ±  0.21; 
p <0.001) than after simvastatin (-0.55 ±
0.16 to -0.47 ± 0.22; p = 0.04; gemfibrozil 
vs simvastatin; p <0.05). In 5 of 45 pa­
tients treated with gemfibrozil, the dense 
subfraction profile was altered into an 
intermediate subfraction profile, with an 
equal amount of buoyant and dense LDL 
particles. The other patients retained a 
dense subfraction profile, expressed as a 
negative value for parameter K, despite 
lipid-lowering therapy.
Fatty acid composition and vitamin E 
content of low-density lipoprotein: The fat­
ty acid composition of each isolated LDL 
was determined (Table III), For technical 
reasons, only the results of 14 patients 
treated with gemfibrozil and 15 patients 
with simvastatin could be analyzed. This 
reduction had no effect on lipid levels, apo-B levels, or 
the value of parameter K before and after therapy in this 
subset when compared with the initial 45 patients. In the 
gemfibrozil group, the relative amount of stearic acid 
(18:0) and oleic acid (18:1) decreased, whereas that of 
linoleic acid (18:2) increased. In the simvastatin group,
TABLE II Changes in the Ratios Cholesterol/Triglyceride, Chalesterol/Apo«B, and 
Triglyceride/Apo-B of the LDL Particles and the Total Cholesterol/HDL Cholesterol 
Ratio After Treatment With Gemfibrozil (n » 19) or Simvastatin (n » 21) in Patients 
With Familial Combined Hyperlipidemia
Before After Change (%) p Value
Cholesterol/ »
triglyceride
G 7.73 ± 2.27 10.26 ± 2.62 53.7 ± 67.0 0.001
S 6.14 ± 1.75 6.14 ± 1.87 1.6 ± 20.9*
Cholestorol/apo-B , 1
G 1.48 ± 0.17 1.54 ± 0.21 5.8 ± 22.0
s 1.34 ± 0,16 1.36 ± 0.16 0.5 ± 12.9
Triglyceride/apo-B
G 0.47 ± 0.11 0.36 ± 0.08 ■17.5 ± 19.3 <0.001
S 0.53 ± 0.13 0.55 i  0.17 5.0 ± 20.21
Total cholesterol/
HDL cholesterol
G 8.4 ± 2.0 6.5 ± 2.2 -22.1 ± 16.5 <0.001
S 9.3 ± 2.6 6,1 ± 1.5 •32.7 *  10.4* <0.001
*p <0.01, Ip <0,001, ip  <0.05; gemfibrozil versus simvaslatin,
Values are presented as mean ± SD,
Abbreviations as in Table 1,
the relative contribution of linoleic acid (18:2) decreased, 
with an increase in arachidonic acid (20:4). Vitamin E 
in LDL decreased significantly with gemfibrozil and was 
unaffected with simvastatin. The ratio o f  polyunsaturat­
ed fatty acids/vitamin E tended to increase after gemfi­
brozil, whereas simvastatin did not affect this ratio.
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TABLE HI Change in Fatty Acid Composition and Vifamin E Content of Total LDL After 
Treatment With Gemfibrozil (n « 14] or Simvastatin (n *» 15) in Patients With Familial 
Combined Hyperlipidemia
Fatty Acids Before After Change (%) p Value
Palmitic acid ¡16:0)
G 22.3 ± 1.9 21.7 ± 1.6 -2.8 ± 6,2
S 23.4 ± 2.2 23.5 ± 2.4 +0.2 ± 5.7
Stearic acid (1 8:0)
G 6.6 ± 0,8 6.3 ± 0,7 -3.1 ± 5,9 0.04
S 6,6 ± 0.6 6,8 ± 0.7 +2.8 ± 6.3*
Oleic acid (18:1)
G 18,7 ± 1.9 17.8 ± 1,6 -4.8 ± 5.7 0.01
S 18.8 ± 1.8 19.0 ± 2.2 +0.9 ± 8.6* «
Linoleic acid (1 8:2)
G 44» 1 ± 3 .7 45.8 ± 3,2 +4.1 ± 4,3 0.01
S 43,4 ± 3.6 41,6 ± 4.1 -4.0 ± 6.01 0.04
Arachidonic acid (20:4)
G 8,2 ± 1.7 8.4 ± 1.6 +3,0 ± 14,5
S 7,8 ± 1.4 9.1 *  1.4 +20.1 ± 21.0* 0.01
Vitamin E§
G 4.06 ± 1.65 3,42 ± 1,66 -16,5 *  18,2 0.004
S 3.65 ± 1.76 3,82 ± 1.68 + 14.0 ± 45,9*
PUFA/Vil. EH
G 846 ± 596 1,102 ± 673 +42 ± 83
S 801 ± 538 727 ± 339 —6 £ 52
*p <0.05, tp <0.001, <0.01; gemfibrozil versus simvastatin.
Values of fatty acids are presented in percentage of total Fatty acids as mean ± SD,
SVilamin E in mg/g low-aensiiy lipoprotein.
tfRalio of polyunsaturated fatty acids/vltamin E in |a.mol/mg,
PUFA => polyunsaturated fatty acids (fimol/mg); Vit, = vitamin; other abbreviations as in Table I.
Total low-density lipoprotein oxidizability: Because of 
technical reasons, the results of only 17 patients treated 
with gemfibrozil versus 18 patients with simvastatin 
could be analyzed, This reduction had no effect on lipid 
and apo-B levels, or the value of parameter K before and 
after therapy in this subset when compared with the ini­
tial 45 patients. Although the lag time at the preoxida- 
tive phase tended to increase, the differences were not 
significant in any of the treatment groups. Oxidation rate 
decreased after simvastatin (p = 0.01), in contrast to gem­
fibrozil, Total amounts of produced conjugated dienes 
(malon dialdehyde reactive products) per milligram of 
LDL protein were similar before and after treatment in 
both groups.
DISCUSSION
The underlying cause of the increased tendency to­
ward cardiovascular diseases in patients with familial 
combined hyperlipidemia is probably related to increased 
levels of small dense LDL and other atherogenic lipopro­
tein remnant particles.8*14,21 A predominance of small 
dense LDL is observed either as a physiologic response 
to lipid abnormalities,22 or as a distinct characteristic of 
the disease with a possible genetic basis.1723 These small 
dense subfractions are associated with atherosclerosis be­
cause of enhanced susceptibility to copper-induced oxi­
dative modification.14 In the present study, we therefore 
investigated the apo-.B-containing lipoprotein concentra­
tions, LDL subfraction profiles, and LDL oxidizability of 
45 affected patients, and evaluated the effects of phar­
macologic intervention on these parameters.
The observed reduction of total plasma cholesterol and 
plasma triglyceride concentrations with simvastatin 
(-22.2%  and -15.9% , respectively) and gemfibrozil
(-12.9% and -48.1% , respectively) 
after 12 weeks of treatment are in accor­
dance with previous reports.24,25 Isola­
tion of VLDL and IDL particles togeth­
er (d <1019 g/ml), instead of isolating 
IDL together with LDL (d >1.006 
g/ml), explains the relatively large con­
tribution of VLDL + IDL cholesterol
i
and the relatively small contribution of 
LDL cholesterol to total plasma cho­
lesterol, and also the large impact of the 
2 therapies on this VLDL + IDL frac­
tion. The increase in HDL cholesterol 
with simvastatin similar to gemfibrozil, 
despite a less pronounced reduction of 
triglyceride concentration after simvas­
tatin, is larger than previously report­
ed.25*26 The decrease and increase in 
LDL cholesterol with simvastatin and 
gemfibrozil, respectively, are also in line 
with other reports.12,13’26 A depletion in 
triglycerides.in the VLDL fraction with 
gemfibrozil, leading to small, more 
dense VLDL + IDL particles that are 
more likely to be converted into LDL 
particles, is suggested to be a cause of 
the observed increase in LDL choles­
terol after gemfibrozil.26,27 
All patients had moderate to severe elevations of apo- 
B levels in accordance with their elevation of lipid lev­
els. In nonnolipidemic subjects, total apo-B-related cho­
lesterol concentration correlates highly with serum 
apo-B. In hypertriglyceridemic states, this correlation is 
less pronounced because of possible underestimation of 
apo-B,28 although the correlation between total choles­
terol minus HDL cholesterol and apo-B in these patients 
was still significant. Both therapies reduced total apo-B 
to a similar extent, but just like the reduction in VLDL 
+ IDL cholesterol/triglyceride and LDL cholesterol, 
gemfibrozil reduced only VLDL + IDL apo-B-contain~ 
ing particles and simvastatin reduced both VLDL + IDL 
and LDL apo-B-containing particles,
Initially, all patients had a dense LDL subfraction pro­
file, both determined by cholesterol content in isolated 
LDL subfractions and described by a continuous vari­
able, parameter K. This method of approach provides 
the opportunity to obtain more detailed information 
about small alterations in the LDL subfraction profile 
than the often-used dichotomous classification in pattern 
A (light) and pattern B (heavy).17 The increase in cho­
lesterol in the buoyant LDLl and LDL2 subtractions 
after gemfibrozil could be explained by the observed 
decrease in the ratio of triglycericle/protein of the LDL 
particle only after gemfibrozil, reflecting an overall 
reduction in triglycerides in the LDL particles. This tri­
glyceride reduction, not observed after simvastatin, is 
associated with more buoyant LDL subfractions.14 It is 
remarkable that despite the substantial reduction in plas­
ma triglyceride concentrations, no patient with a dense 
LDL subfraction profile had complete conversion to a 
buoyant LDL subfraction profile. Only 5 patients had 
conversion to an intermediate profile. These results are
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supported by a recent study by Hokanson et ul29 in which 
they proposed that in familial combined hyperlipidemia, 
small dense LDL and hypertriglyceridemia appear as 
interrelated but separate characteristics and regulated as 
separate processes.
In general, the observed LDL fatty acid composition 
in this group with familial combined hyperlipidemia was 
similar to that found in normal subjects.18 After both 
therapies, only small alterations in this composition were 
seen. The total amount of polyunsaturated fatty acids 
(linoleic and arachidonic acids), most susceptible for 
oxidative modification,18 did not change, On the con­
trary, vitamin E as the major antioxidant in LDL was 
reduced only with gemfibrozil. This may have implica­
tions for total LDL oxidizability.
Our data show only little effect on LDL oxidizabili­
ty after treatment, less than suspected on the basis of a 
more buoyant LDL subfraction profile,14 However, some 
explanations for this lack of change in LDL oxidizabil­
ity are possible: We determined LDL oxidizability in 
total LDL, which is the addition of maximal 5 LDL sub­
tractions, so small changes might be undetected. Despite 
treatment, these patients still had a predominance of 
small dense LDL particles. The ratio of cholesterol/pro­
tein of LDL particles con-elating with LDL oxidizabili­
ty30 was unaffected after both therapies. Finally, the ratio 
of polyunsaturated fatty acids/vitamin E increased only 
with gemfibrozil. This implies that the expected dimin­
ished susceptibility to copper-induced oxidation because 
of a more buoyant LDL subtraction profile14 could be 
offset by a reduced protection of polyunsaturated fatty 
acids from oxidation by vitamin E.
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